Anti-UBE2D2 Antibody
- 产品详情
- 实验流程
Application
| WB, IF/IC |
|---|---|
| Primary Accession | P62837 |
| Reactivity | Human, Mouse, Rat, Pig, Bovine |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 16735 Da |
| Gene ID | 7322 |
|---|---|
| Other Names | PUBC1; UBC4; UBC5B; UBCH4; UBCH5B; Ubiquitin-conjugating enzyme E2 D2; Ubiquitin carrier protein D2; Ubiquitin-conjugating enzyme E2(17)KB 2; Ubiquitin-conjugating enzyme E2-17 kDa 2; Ubiquitin-protein ligase D2; p53-regulated ubiquitin-conjugating enzyme 1 |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human UBE2D2. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IF/IC~~N/A |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | UBE2D2 |
|---|---|
| Synonyms | PUBC1, UBC4, UBC5B, UBCH4, UBCH5B |
| Function | Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:10329681, PubMed:18042044, PubMed:18703417, PubMed:20061386, PubMed:20403326, PubMed:20525694, PubMed:26475854, PubMed:28322253). Catalyzes 'Lys-48'- linked polyubiquitination (PubMed:10329681, PubMed:18042044, PubMed:18359941, PubMed:18703417, PubMed:20061386, PubMed:20403326, PubMed:20525694, PubMed:26475854). Mediates the selective degradation of short-lived and abnormal proteins (PubMed:10329681, PubMed:18042044, PubMed:18359941, PubMed:18703417, PubMed:20061386, PubMed:20403326, PubMed:20525694, PubMed:26475854). Functions in the E6/E6-AP-induced ubiquitination of p53/TP53 (PubMed:15280377). Mediates ubiquitination of PEX5 and SQSTM1 and autoubiquitination of STUB1 and TRAF6 (PubMed:18359941, PubMed:28322253). Involved in the signal-induced conjugation and subsequent degradation of NFKBIA, FBXW2-mediated GCM1 ubiquitination and degradation, MDM2-dependent degradation of p53/TP53 and the activation of MAVS in the mitochondria by RIGI in response to viral infection (PubMed:18703417, PubMed:20403326). Essential for viral activation of IRF3 (PubMed:19854139). |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Jensen J.P.,et al.J. Biol. Chem. 270:30408-30414(1995).
Rolfe M.,et al.Proc. Natl. Acad. Sci. U.S.A. 92:3264-3268(1995).
Guinn B.-A.,et al.Biochem. Biophys. Res. Commun. 335:1293-1304(2005).
Yin Y.,et al.Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP51598
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。